Growing Body of Clinical Evidence Points to the Potential of Profound Medical's TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

Stock Information for Profound Medical Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Profound Medical Corp.

PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS
Profound Medical Receives U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
Profound Medical to Release First Quarter 2024 Financial Results on May 9 - Conference Call to Follow
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.